BIOMARKER:

TMB-H

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Urothelial Cancer

Melanoma

Solid Tumor

Gastric Cancer

Soft Tissue Sarcoma

Squamous Cell Carcinoma of Head and Neck

Biliary Tract Cancer

Colorectal Cancer

Prostate Cancer

Endometrial Cancer

Small Cell Lung Cancer

Pancreatic Adenocarcinoma

Hepatocellular Cancer

Testicular Seminoma

Triple Negative Breast Cancer

Esophageal Cancer

Gastroesophageal Junction Adenocarcinoma

Ovarian Cancer

Pancreatic Cancer

Breast Cancer

Glioblastoma

Bladder Cancer

Thyroid Gland Anaplastic Carcinoma

Lung Cancer

Pancreatic Ductal Adenocarcinoma

Thyroid Gland Medullary Carcinoma

Head and Neck Cancer

Neuroendocrine Tumor

Cervical Cancer

Lung Non-Squamous Non-Small Cell Cancer

HER2 Negative Breast Cancer

Myelodysplastic Syndrome

Basal Cell Carcinoma

Thyroid Gland Papillary Carcinoma

Squamous Cell Skin Cancer

Leiomyosarcoma

Anaplastic Astrocytoma

Thyroid Gland Follicular Carcinoma

Germ Cell Tumors

Peritoneal Cancer

Chordoma

Esophageal Squamous Cell Carcinoma

Thyroid Gland Hurthle Cell Carcinoma

Small Intestinal Carcinoma

Rectal Cancer

Sarcoma

Gallbladder Cancer

Thyroid Gland Carcinoma

Lymphoma

Diffuse Large B Cell Lymphoma

Fallopian Tube Cancer

Testicular Cancer

Vulvar Cancer

Follicular Lymphoma

Nasopharyngeal Carcinoma

Colon Cancer

Penile Cancer

Osteosarcoma

Ewing Sarcoma

Lung Adenocarcinoma

Pituitary Gland Carcinoma

Renal Cell Carcinoma

nivolumab + ipilimumab

TMB-H|Non Small Cell Lung Cancer|nivolumab + ipilimumab

TMB-H|Soft Tissue Sarcoma|nivolumab + ipilimumab

TMB-H|Melanoma|nivolumab + ipilimumab

TMB-H|Solid Tumor|nivolumab + ipilimumab

TMB-H|Urothelial Cancer|nivolumab + ipilimumab

TMB-H|Biliary Tract Cancer|nivolumab + ipilimumab

TMB-H|Pancreatic Adenocarcinoma|nivolumab + ipilimumab

TMB-H|Hepatocellular Cancer|nivolumab + ipilimumab

TMB-H|Prostate Cancer|nivolumab + ipilimumab

TMB-H|Small Cell Lung Cancer|nivolumab + ipilimumab

TMB-H|HER2 Negative Breast Cancer|nivolumab + ipilimumab

TMB-H|Leiomyosarcoma|nivolumab + ipilimumab

TMB-H|Pituitary Gland Carcinoma|nivolumab + ipilimumab

TMB-H|Renal Cell Carcinoma|nivolumab + ipilimumab

pembrolizumab

TMB-H|Non Small Cell Lung Cancer|pembrolizumab

TMB-H|Soft Tissue Sarcoma|pembrolizumab

TMB-H|Melanoma|pembrolizumab

TMB-H|Solid Tumor|pembrolizumab

TMB-H|Urothelial Cancer|pembrolizumab

TMB-H|Squamous Cell Carcinoma of Head and Neck|pembrolizumab

TMB-H|Biliary Tract Cancer|pembrolizumab

TMB-H|Gastric Cancer|pembrolizumab

TMB-H|Pancreatic Adenocarcinoma|pembrolizumab

TMB-H|Colorectal Cancer|pembrolizumab

TMB-H|Prostate Cancer|pembrolizumab

TMB-H|Endometrial Cancer|pembrolizumab

TMB-H|Ovarian Cancer|pembrolizumab

TMB-H|Pancreatic Cancer|pembrolizumab

TMB-H|Triple Negative Breast Cancer|pembrolizumab

TMB-H|Esophageal Cancer|pembrolizumab

TMB-H|Gastroesophageal Junction Adenocarcinoma|pembrolizumab

TMB-H|Breast Cancer|pembrolizumab

TMB-H|Bladder Cancer|pembrolizumab

TMB-H|Thyroid Gland Anaplastic Carcinoma|pembrolizumab

TMB-H|Thyroid Gland Medullary Carcinoma|pembrolizumab

TMB-H|Head and Neck Cancer|pembrolizumab

TMB-H|Neuroendocrine Tumor|pembrolizumab

TMB-H|Cervical Cancer|pembrolizumab

TMB-H|Thyroid Gland Papillary Carcinoma|pembrolizumab

TMB-H|Squamous Cell Skin Cancer|pembrolizumab

TMB-H|Thyroid Gland Follicular Carcinoma|pembrolizumab

TMB-H|Germ Cell Tumors|pembrolizumab

TMB-H|Peritoneal Cancer|pembrolizumab

TMB-H|Chordoma|pembrolizumab

TMB-H|Thyroid Gland Hurthle Cell Carcinoma|pembrolizumab

TMB-H|Small Intestinal Carcinoma|pembrolizumab

TMB-H|Sarcoma|pembrolizumab

TMB-H|Gallbladder Cancer|pembrolizumab

TMB-H|Fallopian Tube Cancer|pembrolizumab

TMB-H|Testicular Cancer|pembrolizumab

TMB-H|Vulvar Cancer|pembrolizumab

TMB-H|Nasopharyngeal Carcinoma|pembrolizumab

TMB-H|Penile Cancer|pembrolizumab

TMB-H|Osteosarcoma|pembrolizumab

TMB-H|Ewing Sarcoma|pembrolizumab

nivolumab

TMB-H|Non Small Cell Lung Cancer|nivolumab

TMB-H|Soft Tissue Sarcoma|nivolumab

TMB-H|Melanoma|nivolumab

TMB-H|Urothelial Cancer|nivolumab

TMB-H|Biliary Tract Cancer|nivolumab

TMB-H|Gastric Cancer|nivolumab

TMB-H|Colorectal Cancer|nivolumab

TMB-H|Prostate Cancer|nivolumab

TMB-H|Small Cell Lung Cancer|nivolumab

TMB-H|Glioblastoma|nivolumab

TMB-H|HER2 Negative Breast Cancer|nivolumab

TMB-H|Anaplastic Astrocytoma|nivolumab

TMB-H|Rectal Cancer|nivolumab

Immunotherapy

TMB-H|Non Small Cell Lung Cancer|Immunotherapy

TMB-H|Melanoma|Immunotherapy

TMB-H|Solid Tumor|Immunotherapy

TMB-H|Urothelial Cancer|Immunotherapy

TMB-H|Biliary Tract Cancer|Immunotherapy

TMB-H|Gastric Cancer|Immunotherapy

TMB-H|Colorectal Cancer|Immunotherapy

TMB-H|Prostate Cancer|Immunotherapy

TMB-H|Endometrial Cancer|Immunotherapy

TMB-H|Breast Cancer|Immunotherapy

TMB-H|Glioblastoma|Immunotherapy

TMB-H|Bladder Cancer|Immunotherapy

TMB-H|Lung Cancer|Immunotherapy

TMB-H|Pancreatic Ductal Adenocarcinoma|Immunotherapy

TMB-H|Thyroid Gland Medullary Carcinoma|Immunotherapy

TMB-H|Lung Non-Squamous Non-Small Cell Cancer|Immunotherapy

TMB-H|Myelodysplastic Syndrome|Immunotherapy

TMB-H|Basal Cell Carcinoma|Immunotherapy

TMB-H|Diffuse Large B Cell Lymphoma|Immunotherapy

TIP

TMB-H|Testicular Seminoma|TIP

PD-L1 inhibitor

TMB-H|Non Small Cell Lung Cancer|PD-L1 inhibitor

TMB-H|Urothelial Cancer|PD-L1 inhibitor

TMB-H|Squamous Cell Carcinoma of Head and Neck|PD-L1 inhibitor

TMB-H|Gastric Cancer|PD-L1 inhibitor

TMB-H|Colorectal Cancer|PD-L1 inhibitor

PD1 inhibitor

TMB-H|Non Small Cell Lung Cancer|PD1 inhibitor

TMB-H|Melanoma|PD1 inhibitor

TMB-H|Squamous Cell Carcinoma of Head and Neck|PD1 inhibitor

TMB-H|Gastric Cancer|PD1 inhibitor

TMB-H|Colorectal Cancer|PD1 inhibitor

TMB-H|Prostate Cancer|PD1 inhibitor

TMB-H|Pancreatic Cancer|PD1 inhibitor

CTLA4 inhibitor

TMB-H|Non Small Cell Lung Cancer|CTLA4 inhibitor

EGFR inhibitor

TMB-H|Lung Adenocarcinoma|EGFR inhibitor

PD-L1 inhibitor + CTLA4 inhibitor

TMB-H|Non Small Cell Lung Cancer|PD-L1 inhibitor + CTLA4 inhibitor

PD1 inhibitor + CTLA4 inhibitor

TMB-H|Non Small Cell Lung Cancer|PD1 inhibitor + CTLA4 inhibitor

FOLFOX

TMB-H|Urothelial Cancer|FOLFOX

TMB-H|Head and Neck Cancer|

pembrolizumab + ipilimumab

TMB-H|Soft Tissue Sarcoma|pembrolizumab + ipilimumab

TMB-H|Melanoma|pembrolizumab + ipilimumab

durvalumab + tremelimumab

TMB-H|Non Small Cell Lung Cancer|durvalumab + tremelimumab

TMB-H|Urothelial Cancer|durvalumab + tremelimumab

TMB-H|Squamous Cell Carcinoma of Head and Neck|durvalumab + tremelimumab

TMB-H|Gastric Cancer|durvalumab + tremelimumab

durvalumab

TMB-H|Non Small Cell Lung Cancer|durvalumab

TMB-H|Urothelial Cancer|durvalumab

TMB-H|Squamous Cell Carcinoma of Head and Neck|durvalumab

TMB-H|Endometrial Cancer|durvalumab

TMB-H|Triple Negative Breast Cancer|durvalumab

atezolizumab

TMB-H|Non Small Cell Lung Cancer|atezolizumab

TMB-H|Melanoma|atezolizumab

TMB-H|Solid Tumor|atezolizumab

TMB-H|Urothelial Cancer|atezolizumab

TMB-H|Triple Negative Breast Cancer|atezolizumab

sintilimab

TMB-H|Non Small Cell Lung Cancer|sintilimab

TMB-H|Solid Tumor|sintilimab

TMB-H|Gastric Cancer|sintilimab

TMB-H|Small Cell Lung Cancer|sintilimab

TMB-H|Gastroesophageal Junction Adenocarcinoma|sintilimab

TMB-H|Pancreatic Ductal Adenocarcinoma|sintilimab

TMB-H|Esophageal Squamous Cell Carcinoma|sintilimab

camrelizumab

TMB-H|Non Small Cell Lung Cancer|camrelizumab

TMB-H|Biliary Tract Cancer|camrelizumab

TMB-H|Gastric Cancer|camrelizumab

TMB-H|Esophageal Cancer|camrelizumab

toripalimab-tpzi

TMB-H|Urothelial Cancer|toripalimab-tpzi

TMB-H|Gastric Cancer|toripalimab-tpzi

TMB-H|Lung Cancer|toripalimab-tpzi

TMB-H|Neuroendocrine Tumor|toripalimab-tpzi

ipilimumab

TMB-H|Melanoma|ipilimumab

TMB-H|Prostate Cancer|ipilimumab

tislelizumab

TMB-H|Solid Tumor|tislelizumab

TMB-H|Gastric Cancer|tislelizumab

TMB-H|Gastroesophageal Junction Adenocarcinoma|tislelizumab

pembrolizumab + lenvatinib

TMB-H|Non Small Cell Lung Cancer|pembrolizumab + lenvatinib

TMB-H|Thyroid Gland Anaplastic Carcinoma|pembrolizumab + lenvatinib

TMB-H|Thyroid Gland Carcinoma|pembrolizumab + lenvatinib

zimberelimab

TMB-H|Gastric Cancer|zimberelimab

TMB-H|Endometrial Cancer|zimberelimab

TMB-H|Esophageal Cancer|zimberelimab

atezolizumab + vemurafenib + cobimetinib

TMB-H|Melanoma|atezolizumab + vemurafenib + cobimetinib

camrelizumab + rivoceranib

TMB-H|Melanoma|camrelizumab + rivoceranib

TMB-H|Small Cell Lung Cancer|camrelizumab + rivoceranib

TMB-H|Cervical Cancer|camrelizumab + rivoceranib

atezolizumab + cobimetinib

TMB-H|Melanoma|atezolizumab + cobimetinib

M7824

TMB-H|Non Small Cell Lung Cancer|M7824

ABT-888

TMB-H|Ovarian Cancer|ABT-888

bevacizumab + atezolizumab

TMB-H|Colorectal Cancer|bevacizumab + atezolizumab

TMB-H|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab + atezolizumab

ABBV-181

TMB-H|Non Small Cell Lung Cancer|ABBV-181

TMB-H|Squamous Cell Carcinoma of Head and Neck|ABBV-181

PF-06801591

TMB-H|Non Small Cell Lung Cancer|PF-06801591

TMB-H|Urothelial Cancer|PF-06801591

dostarlimab-gxly

TMB-H|Non Small Cell Lung Cancer|dostarlimab-gxly

TMB-H|Solid Tumor|dostarlimab-gxly

TMB-H|Endometrial Cancer|dostarlimab-gxly

atezolizumab/hyaluronidase

TMB-H|Non Small Cell Lung Cancer|atezolizumab/hyaluronidase

enfortumab vedotin-ejfv

TMB-H|Urothelial Cancer|enfortumab vedotin-ejfv

nivolumab + ramucirumab

TMB-H|Gastric Cancer|nivolumab + ramucirumab

lisocabtagene maraleucel

TMB-H|Lymphoma|lisocabtagene maraleucel

avelumab + axitinib

TMB-H|Urothelial Cancer|avelumab + axitinib

ABSK091

TMB-H|Urothelial Cancer|ABSK091

avelumab

TMB-H|Urothelial Cancer|avelumab

bevacizumab + sintilimab

TMB-H|Colon Cancer|bevacizumab + sintilimab

durvalumab + ABSK091

TMB-H|Urothelial Cancer|durvalumab + ABSK091

anlotinib + APL-502

TMB-H|Biliary Tract Cancer|anlotinib + APL-502

pembrolizumab + MK-4280

TMB-H|Non Small Cell Lung Cancer|pembrolizumab + MK-4280

STAR0602

TMB-H|Solid Tumor|STAR0602

pembrolizumab + MK-1308

TMB-H|Non Small Cell Lung Cancer|pembrolizumab + MK-1308

venetoclax + obinutuzumab

TMB-H|Follicular Lymphoma|venetoclax + obinutuzumab

pembrolizumab + enzalutamide capsule

TMB-H|Prostate Cancer|pembrolizumab + enzalutamide capsule

lenvatinib

TMB-H|Biliary Tract Cancer|lenvatinib

ABBV-400

TMB-H|Colorectal Cancer|ABBV-400

sintilimab + fruquintinib

TMB-H|Colorectal Cancer|sintilimab + fruquintinib

nivolumab + LY3500518

TMB-H|Non Small Cell Lung Cancer|nivolumab + LY3500518

carboplatin

TMB-H|Urothelial Cancer|carboplatin

cisplatin

TMB-H|Urothelial Cancer|cisplatin

temozolomide

TMB-H|Pituitary Gland Carcinoma|temozolomide